Bard Associates’s NeoGenomics NEO Stock Holding History

Bard Associates’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$348K	Sell	46,865 -520	-1%	-$5.47K	0.09%	102
2025 Q4	$557K	Hold	47,385	–	–	0.14%	93
2025 Q3	$366K	Hold	47,385	–	–	0.1%	129
2025 Q2	$346K	Hold	47,385	–	–	0.11%	132
2025 Q1	$450K	Sell	47,385 -20	-0%	-$250	0.17%	122
2024 Q4	$781K	Sell	47,405 -200	-0.4%	-$3.11K	0.27%	97
2024 Q3	$702K	Sell	47,605 -160	-0.3%	-$2.5K	0.24%	111
2024 Q2	$663K	Hold	47,765	–	–	0.25%	109
2024 Q1	$751K	Hold	47,765	–	–	0.27%	105
2023 Q4	$773K	Sell	47,765 -700	-1%	-$11.5K	0.29%	94
2023 Q3	$596K	Hold	48,465	–	–	0.25%	113
2023 Q2	$779K	Hold	48,465	–	–	0.3%	97
2023 Q1	$844K	Hold	48,465	–	–	0.35%	93
2022 Q4	$448K	Hold	48,465	–	–	0.19%	116
2022 Q3	$417K	Hold	48,465	–	–	0.19%	114
2022 Q2	$395K	Buy	48,465 +765	+2%	+$7.3K	0.17%	125
2022 Q1	$580K	Hold	47,700	–	–	0.2%	121
2021 Q4	$1.63M	Sell	47,700 -4,400	-8%	-$172K	0.54%	68
2021 Q3	$2.51M	Hold	52,100	–	–	0.85%	44
2021 Q2	$2.35M	Sell	52,100 -38,100	-42%	-$1.69M	0.77%	52
2021 Q1	$4.35M	Sell	90,200 -1,300	-1%	-$67.7K	1.57%	12
2020 Q4	$4.93M	Sell	91,500 -300	-0.3%	-$13.6K	1.94%	8
2020 Q3	$3.39M	Sell	91,800 -200	-0.2%	-$7.43K	1.8%	8
2020 Q2	$2.85M	Hold	92,000	–	–	1.58%	14
2020 Q1	$2.54M	Sell	92,000 -14,500	-14%	-$434K	1.87%	11
2019 Q4	$3.12M	Sell	106,500 -6,000	-5%	-$143K	1.58%	13
2019 Q3	$2.15M	Sell	112,500 -800	-0.7%	-$18.8K	1.09%	25
2019 Q2	$2.49M	Sell	113,300 -5,700	-5%	-$125K	1.24%	21
2019 Q1	$2.44M	Sell	119,000 -14,550	-11%	-$253K	1.23%	17
2018 Q4	$1.68M	Sell	133,550 -62,943	-32%	-$938K	0.97%	30
2018 Q3	$3.02M	Sell	196,493 -1,140	-0.6%	-$15.8K	1.39%	15
2018 Q2	$2.59M	Sell	197,633 -48,850	-20%	-$538K	1.2%	17
2018 Q1	$2.01M	Sell	246,483 -7,000	-3%	-$56.7K	1%	28
2017 Q4	$2.25M	Sell	253,483 -3,140	-1%	-$29K	1.08%	24
2017 Q3	$2.86M	Sell	256,623 -8,600	-3%	-$83.7K	1.33%	17
2017 Q2	$2.38M	Sell	265,223 -1,100	-0.4%	-$8.73K	1.08%	23
2017 Q1	$2.1M	Sell	266,323 -22,600	-8%	-$184K	0.98%	29
2016 Q4	$2.48M	Sell	288,923 -4,000	-1%	-$34.3K	1.15%	24
2016 Q3	$2.41M	Sell	292,923 -2,080	-0.7%	-$17.5K	1.18%	23
2016 Q2	$2.37M	Sell	295,003 -24,420	-8%	-$196K	1.26%	23
2016 Q1	$2.15M	Sell	319,423 -4,600	-1%	-$30.3K	1.24%	22
2015 Q4	$2.55M	Sell	324,023 -117,927	-27%	-$864K	1.5%	13
2015 Q3	$2.53M	Sell	441,950 -19,500	-4%	-$121K	1.46%	13
2015 Q2	$2.5M	Sell	461,450 -23,450	-5%	-$121K	1.24%	19
2015 Q1	$2.26M	Sell	484,900 -6,200	-1%	-$27K	1.09%	24
2014 Q4	$2.05M	Sell	491,100 -1,000	-0.2%	-$4.59K	0.96%	37
2014 Q3	$2.56M	Sell	492,100 -8,800	-2%	-$45.2K	1.2%	22
2014 Q2	$1.66M	Sell	500,900 -10,200	-2%	-$33.9K	0.66%	55
2014 Q1	$1.77M	Sell	511,100 -10,900	-2%	-$40.8K	0.75%	47
2013 Q4	$1.91M	Sell	522,000 -9,700	-2%	-$33.7K	0.79%	41
2013 Q3	$1.59M	Sell	531,700 -6,000	-1%	-$16.9K	0.71%	48
2013 Q2	$2.14M	Buy	+537,700	New	+$2.05M	1%	30

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Bard Associates's NEO Position: Q1 2026 in Review

Bard Associates reduced its NeoGenomics (NEO) stake by 1.1% in Q1 2026, selling an estimated $5.47K and leaving 46,865 shares worth $348K. The position accounts for 0.09% of the portfolio, ranked #102.

Bard Associates first reported a position in NEO in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.93M in Q4 2020. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

Bard Associates held 46,865 shares of NeoGenomics worth $348K as of Q1 2026.
Bard Associates sold 520 NeoGenomics shares in Q1 2026, an estimated $5.47K.
NeoGenomics made up 0.09% of Bard Associates's portfolio in Q1 2026, its #102 holding.
Bard Associates first reported a position in NeoGenomics in Q2 2013 and has held it in 52 quarters since.
Bard Associates's NeoGenomics position peaked at $4.93M in Q4 2020.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Bard Associates's 13F filing for Q1 2026, filed 8 May 2026.